Doctor of Osteopathy Program year 2019 Source: CMS Open Payments, 2026 publication

Tammy Huizenga

Family Medicine Grand Rapids, MI Doctor of Osteopathy

NPI 1003816224 CMS profile 790431

3700 52Nd St Se, Grand Rapids, MI 49512

Open in the dashboard

General payments

$29

1 record reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Tammy Huizenga of Grand Rapids, MI is reported in the CMS Open Payments database as having received $29 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 13th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $29 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tammy Huizenga
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Tammy Huizenga were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Tammy Huizenga Family Medicine median Middle half National median
2019 $29 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program year 2019
  1. Janssen Biotech, Inc. $29 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $29 1 payment
Products named General payments · program year 2019
  1. SIMPONI $29 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,331

Median for General Practice: 1,105

Drug cost

$66,624

Median for General Practice: $48,734

Branded share of claims

43.7%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Armour Thyroid Thyroid,pork Brand 281 $19,835
Trulicity Dulaglutide Brand 18 $19,023
Np Thyroid Thyroid,pork Brand 119 $5,371
Pristiq Desvenlafaxine Succinate Brand 12 $5,016
Estradiol Generic 21 $3,310
Tirosint Levothyroxine Sodium Brand 25 $3,135
Levothyroxine Sodium Generic 172 $1,872
Liothyronine Sodium Generic 43 $1,269
Valacyclovir Valacyclovir Hcl Brand 19 $923
Amlodipine Besylate Generic 69 $921

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$55,491

Of which drugs: $703

Medicare patients

268

Average age 73

Services billed

7,266

193 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 46%
Arthritis 45%
Ischemic heart disease 16%
Cancer 16%
Atrial fibrillation 15%
Depression 15%
Diabetes 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, estradiol valerate, up to 10 mg J1380 Office 19 82 $476
Injection, ceftazidime, per 500 mg J0713 Office 15 56 $65
Injection, testosterone cypionate, 1 mg J1071 Office 13 4,735 $62

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record